DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry.
Phase 1
Recruiting
- Conditions
- Atopic eczemaMedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2023-504171-24-00
- Lead Sponsor
- Amsterdam UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 216
Inclusion Criteria
The subject is an adult., The subject has a diagnosis of atopic eczema., The subject receives dupilumab 300 mg every 2 weeks for the treatment of atopic eczema., The subject has controlled disease according to the Treat-to-Target criteria., The subject has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.
Exclusion Criteria
The subject uses or initiates other systemic immunomodulating therapy for atopic eczema or another diagnosis.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method